AYTU BIOPHARMA, INC
Income Statement
| Line Item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.4M | $15.2M | $13.9M | $15.1M | $18.5M | $16.2M | $16.6M | $14.6M |
| Cost of Revenue | $4.8M | $5.5M | $4.7M | $4.9M | $5.6M | $5.4M | $4.6M | $3.5M |
| Gross Profit | $7.6M | $9.6M | $9.2M | $10.3M | $12.8M | $10.8M | $12.0M | $11.1M |
| Gross Margin | 61.2% | 63.5% | 66.1% | 67.8% | 69.4% | 66.5% | 72.3% | 75.7% |
| Operating Expenses | ||||||||
| Research & Development | $0 | $0 | $0 | $216.0K | $162.0K | $522.0K | $426.0K | $1.0M |
| SG&A Expense | $5.0M | $5.1M | $4.9M | $3.7M | $4.1M | $4.4M | $5.1M | $4.0M |
| Operating Income | $-4.1M | $-2.0M | $-1.5M | $-7.6M | $2.4M | $-1.7M | $-930.0K | $-2.3M |
| Operating Margin | -32.7% | -13.0% | -10.8% | -50.4% | 13.1% | -10.4% | -5.6% | -15.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-5.6M | $-10.6M | $2.0M | $-19.4M | $3.8M | $382.0K | $1.5M | $-2.5M |
| Income Tax Expense | $10.0K | $0 | $0 | $437.0K | $-122.0K | $-283.0K | $405.0K | $841.0K |
| Net Income | $-5.6M | $-10.6M | $2.0M | $-19.8M | $4.0M | $788.0K | $1.5M | $-4.6M |
| Net Margin | -45.3% | -69.8% | 14.1% | -130.9% | 21.6% | 4.9% | 8.9% | -31.6% |
| EPS (Basic) | $-0.53 | $-1.05 | $0.21 | $-3.18 | $0.65 | $0.13 | $0.24 | $-0.82 |
| EPS (Diluted) | $-0.53 | $-1.05 | $-0.08 | — | $0.21 | $-0.26 | $-0.15 | — |
| Shares Outstanding (Basic) | 10.5M | 10.0M | 9.4M | 6.3M | 6.1M | 6.1M | 6.1M | 5.5M |
| Shares Outstanding (Diluted) | 10.5M | 10.0M | 19.5M | 6.3M | 8.2M | 8.5M | 9.1M | 5.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |